

I. Epidemiological profile

Population	2013	%
High transmission (> 1 case per 1000 population)	33 800 000	90
Low transmission (0–1 cases per 1000 population)	3 760 000	10
Malaria-free (0 cases)	0	0
Total	37 560 000	

Parasites and vectors	
Major plasmodium species:	<i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)
Major anopheles species:	<i>An. gambiae</i> , <i>An. funestus</i> , <i>An. funestus</i>
Programme phase:	Control
Reported confirmed cases:	1 502 362
Reported deaths:	7 277

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2006
	ITNs/LLINs distributed to all age groups	Yes	2013
IRS	IRS is recommended	Yes	2005
	DDT is authorized for IRS	Yes	2008
Larval control	Use of larval control recommended	Yes	2011
IPT	IPT used to prevent malaria during pregnancy	Yes	1998
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2012
	Malaria diagnosis is free of charge in the public sector	Yes	2001
Treatment	ACT is free for all ages in public sector	Yes	2005
	Artemisinin-based monotherapies withdrawn	–	–
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	–
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	–
	G6PD test is a requirement before treatment with primaquine	No	–
	Directly observed treatment with primaquine is undertaken	No	–
	System for monitoring of adverse reactions to antimalarials exists	Yes	–


Intervention	Policies/strategies	Yes/No	Year adopted
Surveillance	ACD for case investigation (reactive)	No	–
	ACD of febrile cases at community level (pro-active)	No	–
	Mass screening is undertaken	No	–
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	–
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	–

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	AL	2004
First-line treatment of <i>P. falciparum</i>	AL	2004
Treatment failure of <i>P. falciparum</i>	QN	2004
Treatment of severe malaria	AS; QN	2012
Treatment of <i>P. vivax</i>	–	–
Dosage of primaquine for radical treatment of <i>P. vivax</i>	–	–
Type of RDT used	–	–


Therapeutic efficacy tests (clinical and parasitological failure, %)

Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
–	–	–	–	–	–	–	–


III. Financing




Financing by intervention in 2013




IV. Coverage



Cases tested and treated in public sector




Cases tracked




Test positivity



V. Impact



Malaria admissions and deaths (per 100 000)



Impact: Insufficiently consistent data to assess trends